Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.

NCT02194842 is registered in ClinicalTrials.gov with European Organisation for Research and Treatment of Cancer - EORTC as lead sponsor.

NCT NCT02194842
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02194842 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 31, 2015
Completion date
December 31, 2028
Enrollment
446 (actual)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer